All Releases
 |
BioCryst Pharmaceuticals Announces Presentation of Forodesine Data at the 45th Annual Meeting of the American Society of Clinical Oncology
May 14, 2009
|
11.3 KB |
| |
BIRMINGHAM, Ala., May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced long-term data from a Phase 2 study of forodesine, the Company's lead oncology compound, in patients with cutaneous T-cell lymphoma (CTCL). The data will be presented at the 45th Annual Meeting of the American So...
|
|
BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
May 8, 2009
|
17.2 KB |
| |
BIRMINGHAM, Ala., May 8, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its inventory of finished pera...
|
|
BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
May 7, 2009
|
7.8 KB |
| |
BIRMINGHAM, Ala., May 7, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that an update regarding peramivir and its first quarter 2009 financial results will be released on Friday, May 8, 2009. Following the release, BioCryst will host a conference call and Web cast at 8:30 a.m. Easter...
|
|
Data from Phase 2 Study of Peramivir in Patients Hospitalized with Influenza Presented at the XI International Symposium on Respiratory Viral Infections
Feb 23, 2009
|
12.3 KB |
| |
BIRMINGHAM, Ala., Feb 23, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that the full data set from an exploratory Phase 2 study of peramivir in patients hospitalized for influenza was presented by the study's Principal Investigator, Dr. Michael G. Ison, Assistant Professor, Divisions...
|
|
BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
Feb 6, 2009
|
18.5 KB |
| |
BIRMINGHAM, Ala., Feb 06, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the fourth quarter and year ended December 31, 2008.
Fourth Quarter 2008 Financial Results
For the three months ended December 31, 2008, the Company reported collaborative and other r...
|
|
BioCryst to Present at the 11th Annual BIO CEO & Investor Conference
Feb 2, 2009
|
9.2 KB |
| |
BIRMINGHAM, Ala., Feb 02, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, will present a corporate update at the 11th Annual BIO CEO & Investor Conference on Monday, February 9, 2009 at 11:30 a.m. Eastern T...
|
|
BioCryst Pharmaceuticals to Announce Fourth Quarter and Year End 2008 Financial Results on February 6, 2009
Jan 30, 2009
|
10.1 KB |
| |
BIRMINGHAM, Ala., Jan 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its fourth quarter and fiscal year 2008 financial results will be released on Friday, February 6, 2009. Following the release, BioCryst will host a conference call and Web cast at 8:30 a.m. Eastern Time to di...
|
|
BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
Jan 8, 2009
|
9.8 KB |
| |
BIRMINGHAM, Ala., Jan 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer and Dr. William P. Sheridan, Chief Medical Officer of BioCryst, will present a corporate update at the J.P. Morgan 27th Annual Healthcare Confere...
|
|
BioCryst Pharmaceuticals Elects Stanley C. Erck to its Board of Directors
Dec 23, 2008
|
10.4 KB |
| |
BIRMINGHAM, Ala., Dec 23, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Stanley C. Erck has been elected to the Company's Board of Directors. Mr. Erck has over twenty years of experience in the biotechnology industry, most recently serving as President and Chief Executive ...
|
|
BioCryst Pharmaceuticals Continues Forodesine HCl Program in Chronic Lymphocytic Leukemia
Dec 22, 2008
|
11.9 KB |
| |
BIRMINGHAM, Ala., Dec 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced interim data from the ongoing Forodesine HCl Phase 2 program in patients with chronic lymphocytic leukemia (CLL) and data from a healthy subject pharmacokinetic and pharmacodynamic study. The CLL study will conti...
|
|
BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
Dec 5, 2008
|
10.4 KB |
| |
BIRMINGHAM, Ala., Dec 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) announced today that the Company will present pre-clinical data on Forodesine HCl and BCX-4208, and clinical data on BCX-4208 at the 50th American Society of Hematology (ASH) Annual Meeting and Exposition being held in San Franci...
|
|
BioCryst Pharmaceuticals Ranked Number 29 in Deloitte's Technology Fast 500 Program for Fastest Growing Companies in North America
Nov 26, 2008
|
7.8 KB |
| |
Birmingham, AL - November 26, 2008 - BioCryst Pharmaceuticals has been named number 29 on Deloitte's 2008 Technology Fast 500, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies in North America. Rankings are based on percentage of fiscal year revenue growth over five years, from 2003-2007. ...
|
|
BioCryst to Present at the Rodman and Renshaw 10th Annual Healthcare Conference
Nov 3, 2008
|
10.1 KB |
| |
BIRMINGHAM, Ala., Nov 03, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, President and Chief Executive Officer of BioCryst, will present a corporate update at the Rodman and Renshaw 10th Annual Healthcare Conference in New York on Monday, November 10, 2008...
|
|
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Oct 31, 2008
|
17.1 KB |
| |
BIRMINGHAM, Ala., Oct 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced financial results for the quarter ended September 30, 2008.
Third Quarter 2008 Financial Results
For the three months ended September 30, 2008, the Company reported collaborative and other research a...
|
|
BioCryst Reports Positive Results From a Phase 2 Study of Intravenous Peramivir for Outpatient Influenza
Oct 28, 2008
|
13.1 KB |
| |
BIRMINGHAM, Ala., Oct 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- A Single Dose of Peramivir is Effective and Well-Tolerated at Both 300 mg and 600 mg Dose Levels. The study, sponsored by BioCryst's partner for peramivir, Shionogi & Co., Ltd., was accepted as a presentation at the 48th Interscience Conference on Antimicrobial Agents ...
|
|
BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
Oct 27, 2008
|
13.5 KB |
| |
BIRMINGHAM, Ala., Oct 27, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced results of an exploratory Phase 2 trial of intravenous (i.v.) peramivir, a neuraminidase inhibitor, in patients hospitalized for acute serious or potentially life-threatening influenza. The Phase 2 trial com...
|
|
BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
Oct 24, 2008
|
10.4 KB |
| |
BIRMINGHAM, Ala., Oct 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its third quarter 2008 financial results will be released on Friday, October 31, 2008. Following the release, BioCryst will host a conference call and Web cast at 8:30 a.m. Eastern Time to discuss the financi...
|
|
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Oct 20, 2008
|
11.4 KB |
| |
BIRMINGHAM, Ala., Oct 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) and partner Shionogi & Co., Ltd. (Shionogi) today announced that positive Phase 2 data on peramivir, a potent neuraminidase inhibitor for the treatment of influenza, has been accepted as a late-breaker poster at the 48th Intersci...
|
|
BioCryst to Present at the JMP Healthcare Focus Conference
Oct 1, 2008
|
10.1 KB |
| |
BIRMINGHAM, Ala., Oct 01, 2008 /PRNewswire via COMTEX News Network/ -- BIRMINGHAM, Ala., Oct. 1 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, Chief Executive Officer and President of BioCryst, will present a corporate update at the JMP Healthcare Focus Conference in New York on Monda...
|
|
BioCryst to Present at UBS 2008 Global Life Sciences Conference
Sep 16, 2008
|
10.1 KB |
| |
BIRMINGHAM, Ala., Sept 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Jon P. Stonehouse, Chief Executive Officer and President of BioCryst, will present a corporate update at the UBS 2008 Global Life Sciences Conference in New York on Tuesday, September 23, 2008 at 2:00 ...
|
|
|
